TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed invasive breast cancer by core needle or incisional biopsy (excisional biopsy is not allowed). Clinical stage T2-3 N0-2 or T1 N1-2 by physical exam or radiologic studies.~2. Documented Breast Cancer Gene (BRCA) germline mutation testing.~3. Estrogen Receptor (ER)-, Progesterone Receptor (PR)-, and Human Epidermal Growth Factor Receptor (HER)2-negative (triple-negative) cancer of the breast.~4. ECOG Performance status of 0 to 1.~5. Women must be determined to be not of childbearing potential (surgically sterile, or postmenopausal defined as amenorrheic for at least 12 months) by the Investigator OR they must have a negative serum pregnancy test prior to randomization.~Exclusion Criteria:~1. Previous anti-cancer treatment (cytotoxic chemotherapy, immunotherapy, biologic therapy radiotherapy or investigational agents) with therapeutic intent for current breast cancer.~2. Previous treatment with carboplatin, paclitaxel, doxorubicin, cyclophosphamide and a Poly-(ADP-ribose)-Polymerase (PARP) inhibitor.~3. Concurrent treatment with an ovarian hormonal replacement therapy or with hormonal agents such as raloxifene, tamoxifen or other selective estrogen receptor modulator (SERM). Subjects must have discontinued use of such agents prior to beginning study treatment.~4. A history of seizure within 12 months prior to study entry.~5. Pre-existing neuropathy from any cause in excess of Grade 1.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): Veliparib + carboplatin + paclitaxel followed by doxorubicin/cyclophosphamide (AC)
- Arm C (Type: PLACEBO_COMPARATOR): Placebo + placebo + paclitaxel followed by AC.
- Arm B (Type: PLACEBO_COMPARATOR): Placebo + carboplatin + paclitaxel followed by AC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Fasting, calculated mean LDL-C ≥130 mg/dL and ≤220 mg/dL~* Fasting mean TG level ≤400 mg/dL~* Stable statin therapy for at least 3 months prior to screening: atorvastatin (10 or 20 mg daily), simvastatin (5, 10 or 20 mg daily), rosuvastatin (5 or 10 mg daily), or pravastatin (10, 20 or 40 mg daily)~Exclusion Criteria:~* Clinically significant cardiovascular disease within 12 months of screening~* Current muscle-related symptoms that may be due to ongoing statin therapy or a history of certain lab abnormalities that occurred during statin therapy and resolved when statin therapy was discontinued~* Type 1 diabetes or uncontrolled type 2 diabetes~* Use of metformin or thiazolidinediones (TZD) within 4 weeks of screening~* History of chronic musculoskeletal symptoms such as fibromyalgia~* Uncontrolled hypothyroidism~* Liver disease or dysfunction~* Renal dysfunction or nephritic syndrome~* Gastrointestinal conditions or procedures or surgeries~* Hematologic or coagulation disorders or low hemoglobin levels~* HIV or AIDS~* History of malignancy~* History of drug or alcohol abuse within 2 years~* Use of experimental or investigational drugs within 30 days of screening~* Use of ETC-1002 in a previous clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ETC-1002 120 mg/day (Type: EXPERIMENTAL): Orally, once daily in morning as capsules
- ETC-1002 180 mg/day (Type: EXPERIMENTAL): Orally, once daily in morning as capsules
- Placebo (Type: PLACEBO_COMPARATOR): Orally, once daily in morning

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non small cell lung cancer, Stage IIIB or Stage IV~* One and only 1 prior platinum-based chemotherapy~* No other uncontrolled concurrent illness~* Use of highly effective birth control methods in males or females with reproductive potential~Exclusion Criteria:~* Previous participation in another trial within the last 4 weeks~* Surgery within 10 days prior to the start of study treatment~* Brain metastases~* Confirmed diagnosis of infection with the human immunodeficiency virus (HIV)~* Current treatment with warfarin sodium (Coumadin) or similar anticoagulation medication~* Breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Self-identified man who has sex with men~* Age 18 years or older~* Able to communicate in both written and oral english~* HIRI-MSM score greater than or equal to 10~* At least one self-reported unprotected receptive anal sex act over the preceding 6 months~* Creatinine clearance greater than or equal to 60mL/min by Modified Diet in Renal Disease (MDRD) formula~* HIV un-infected at screening using standard ELISA and Western Blot testing~Exclusion Criteria:~* Clinical signs or symptoms suggestive of an HIV seroconversion illness within the last 3 months in the opinion of the investigator~* Use of pre- or post-exposure prophylaxis within the last 3 months~* Use of concomitant nephrotoxic drugs~* Use of concomitant immune modulatory drugs~* Hepatitis B surface antigen positivity~* Any condition or concomitant medication portending an increased risk of osteoporosis~* Enrollment in any other HIV prevention program or trial

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Tenofovir/emtricitabine (Type: EXPERIMENTAL): MSM receiving once daily TDF/FTC-based (Truvada®) pre-exposure prophylaxis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ventilation and Pulmonary Endothelium Toxicities of E-cigarettes: A Randomized Crossover Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* current use of e-cigarettes (\>1x/month but \<4 days/week)~Exclusion Criteria:~* any chronic medical or major psychiatric problems including current asthma~* self-reported heavy snoring/sleep apnea~* pre-bronchodilator FEV1 or FVC \<80% predicted or FEV1/FVC \< lower limit of normal~* MRI exclusions (pregnancy, claustrophobia, metal in body, gadolinium allergy, eGFR \<60 mL/min/1.73m2)~* MRI scan with contrast within the last 12 months or planned MRI with contrast in the next 6 months~* use of any of the following in the prior 30 days: any conventional cigarettes, marijuana \>10 days, any illicit drugs, any medication or inhalers (excluding hormonal contraceptives)~* binge drinking (≥5 alcoholic beverages over 2 hours) over the prior two weeks~* adverse symptomatic response to the study e-cigarette exposure (e.g., palpitations, shortness of breath, chest pain, headache, dizziness)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- E-cigarette first (Type: EXPERIMENTAL): Participants will undergo the e-cigarette exposure prior to the first two MRI measures, and then they will undergo the sham exposure prior to the last two MRI measures. The two MRIs performed under both experimental exposures (e-cigarette and sham) will be enhanced by (1) gadolinium and then (2) hyperpolarized 3-helium.
- Sham first (Type: EXPERIMENTAL): Participants will undergo the sham exposure prior to the first two MRI measures, and then they will undergo the e-cigarette exposure prior to the last two MRI measures. The two MRIs performed under both experimental exposures (e-cigarette and sham) will be enhanced by (1) gadolinium and then (2) hyperpolarized 3-helium.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) can and will comply with the requirements of the protocol.~* Subjects who received the complete three-dose primary vaccination course in study NCT01021293.~* Healthy male or female toddlers 18 to 24 months of age at the time of Visit 1 (Day 0).~* Written informed consent obtained from the parent(s)/ Legally Acceptable Representative(s) of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~Exclusion Criteria:~* Child in care.~* Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the booster dose of study vaccine(s), or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to Visit 1 (Day 0).~* Administration of immunoglobulins and/or any blood products within the 3 months preceding Visit 1 (Day 0) or planned administration during the study period.~* Administration of a vaccine not foreseen by the study protocol within 30 days of Visit 1 (Day 0) or planned administration during the study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Evidence of previous booster vaccination against poliomyelitis or the disease since the conclusion visit of Study NCT01021293.~* History of seizures or progressive neurological disease.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.~* Major congenital defects or serious chronic illness.~* Acute disease and/or fever at the time of enrolment.

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 24 Months
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Subjects in this group will receive the GSK Biologicals' IPV vaccine at 18 months of age. Subjects will also receive a dose of DTPa/Hib (Infanrix+Hib) as part of the local standard of care.
- Group B (Type: ACTIVE_COMPARATOR): Subjects in this group will receive only a booster dose of GSK Biologicals' DTPa/Hib vaccine (Infanrix+Hib) as part of the local standard of care and will not be associated with any study endpoint.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cisplatin and Radiation Therapy in Treating Patients With Stage IV Cancer of the Head and Neck

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx No distant metastatic disease No previous or concurrent head and neck primaries No lip, nasopharynx, or salivary gland lesions No recurrent tumors Stage IV disease comprised of T4 NO-3 lesions~PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: Karnofsky greater than 60 Life Expectancy: Not specified Hematopoietic: ANC greater than 2,000 Platelet count greater than 100,000 Hepatic: Not specified Renal: Creatinine clearance greater than 50 mL/min Cardiovascular: Not specified Other: Not pregnant or nursing No adverse medical illnesses No imaging studies performed greater than one month preregistration No laboratory studies greater than 2 weeks preregistration No other malignancies, except for basal or squamous cell of the skin, within the past 5 years~PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to the head and neck Surgery: No prior surgery to study site other than a biopsy Other: Protocol treatment must begin within 8 weeks of biopsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~- Healthy male or female subjects~Exclusion criteria:~- Any relevant deviation from healthy condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- FDC first, fasted (Type: EXPERIMENTAL): Linagliptin/Metformin FDC followed by single tablets of linagliptin and metformin, fasted
- Single tablets first, fasted (Type: EXPERIMENTAL): single tablets of linagliptin and metformin followed by Linagliptin/Metformin FDC, fasted
- FDC first, fed (Type: EXPERIMENTAL): Linagliptin/Metformin FDC followed by single tablets of linagliptin and metformin, fed
- Single tablets first, fed (Type: EXPERIMENTAL): single tablets of linagliptin and metformin followed by Linagliptin/Metformin FDC, fed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Parathyroid Hormone (PTH) on Osseous Cavity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age range: 30 to 75 years~* Sex: Male and female~* Female patients must be postmenopausal (for at least 2 years), surgically sterilized or utilizing one of the following methods of birth control throughout the trial - IUD, diaphragm, Depo-Provera, Norplant, oral contraceptive with condom or spermicidal gel/foam with a condom, or abstinence~* Patients must be able and willing to follow study procedures and instructions~* Patients must have read, understood and signed an informed consent form~* Patients must have localized or generalized, advanced periodontal disease (American Dental Association Class 4)~* Patients must present with at least 10 teeth in the functional dentition~* Each patient must have at least one tooth with the following criteria to enter the study:~  * Periodontal probing depths of \> 6 mm to \< 14 mm~ * Attachment loss of \> 6 mm to \< 14 mm~ * Bleeding on probing~Exclusion Criteria:~* Patients under 30 years of age~* Female patients who are pregnant (as determined by positive urine pregnancy test at screening) or lactating, or female patients who are of childbearing potential who are not using hormonal, barrier methods of birth control or abstinence.~* Patients who are using hormonal contraceptives must have started the method not fewer than 30 days prior to the screening examination.~* Patients with metabolic bone diseases such as Paget's disease, hypercalcemia, vitamin D3 abnormalities or any other metabolic bone disease including osteoporosis. (If Vitamin D levels are low (\> 20 ng/ml - 24 ng/ml), dietary supplementation will be initiated and levels re-evaluated after 4 weeks and reconsidered for inclusion at that time.)~* Patients with prior radiation treatment, bone metastasis or other skeletal malignancy~* Patients on medications that would affect bone metabolism~* Patients with growth hormone deficiency~* Patients with uncontrolled diabetes, sprue, inflammatory bowel disease or other disorders that would affect calcium absorption.~* Patients who are heavy smokers (\> 1 pack/day); Patients on bisphosphonates, including Fosamax~* Patients with any form of kidney disease including kidney stones (urolithiasis and nephrolithiasis); and~* Patients on digitalis therapy

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- FORTEO (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-65 years old~* Diagnosed with Schizophrenia or Schizoaffective disorder~* Ability to visit the doctor's office for scheduled visits~Exclusion Criteria:~* Women who are pregnant or breastfeeding~* Have a body mass index (BMI) greater than 40~* Have diabetes, heart disease or any other unstable illness~* Have known positive human immunodeficiency virus (HIV)~* Are currently taking olanzapine, risperidone, clozapine, glucocorticoids, injectable antipsychotics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Olanzapine (Type: EXPERIMENTAL): None
- Risperidone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meet the 1984 Modified New York Criteria for Classification of Ankylosing Spondylitis~* With axial involvement~* Without peripheral joint involvement (synovitis) at the time of study entry, (excluding involvement of the hips, knees and shoulders)~* Need for daily treatment with NSAIDs during the previous 30 days before study entry~Exclusion Criteria:~* Known inflammatory enteropathy (eg, ulcerative colitis, Crohn's disease, etc)~* Presence of extra-articular manifestations (eg, uveitis, endocarditis, etc.)~* Known vertebral compression~* Need for a corset during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Celecoxib 200 mg QD (Type: EXPERIMENTAL): None
- Diclofenac SR 75 mg QD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study of the Impact of RoActemra/Actemra on Fatigue in Patients With Rheumatoid Arthritis (PEPS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/= 18 years of age~* Moderate to severe rheumatoid arthritis~* Inadequate response to disease-modifying antirheumatic drugs (DMARDS) or anti-TNF (tumor necrosis factor) drugs~Exclusion Criteria:~* Hypersensitivity to RoActemra/Actemra or any component~* Active infection~* Participation in a clinical trial in rheumatoid arthritis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab (Type: None): Eligible participants receiving tocilizumab according to summary of product characteristics in a real life setting will be observed for 4 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete